Abstract: Objective To explore the value of the treatment and application of rivastigmine bitartrate capsules combined with selegiline in the treatment of Parkinson’s disease. Methods A total of 80 patients with Parkinson’s disease who were admitted to the Department of Neurology of Goerroth Mongolian Autonomous County Hospital from October 2020 to September 2021 were selected as the research subjects. According to the random number table method, they were divided into control group and study group, with 40 patients in each group. Control group was given selegiline treatment, study group was given carbalatin ditartrate capsule combined selegiline treatment, treatment effect, adverse reactions, IGF-1 （insulin growth factor） and Aβ1-42 （human β -amyloid polypeptide 1-42）, quality of life, cognitive function after treatment,score of Parkinson’s disease in 2 groups were compared. Results After treatment, IGF-1 and Aβ1-42 in study group were higher than those in control group, and the difference was statistically significant （P<0.05）. There was no significant difference in the incidence of adverse reactions between 2 groups （P>0.05）. The therapeutic effect of the study group was higher than that of the control group, and the difference was statistically significant （P<0.05）. After treatment, the SF-36 score of patients in the study group was higher than that in the control group, the difference was statistically significant （P<0.05）; The cognitive function of the study group was higher than that of the control group, and the difference was statistically significant （P<0.05）. Before treatment, there was no significant difference in the comprehensive score of Parkinson’s disease between study group and control group （P>0.05）. After treatment, the comprehensive score of Parkinson’s disease in study group was lower than that in control group, and the difference was statistically significant （P<0.05）. Conclusion Rivastigmine Bitartrate Capsules combined with selegiline in the treatment of Parkinson’s disease can acan adjust the relevant serological indicators of patients, improve the quality of life and cognitive function of patients, improve the therapeutic effect, worthy of clinical application.

Key words: Rivastigmine bitartrate capsules, selegiline, parkinson's disease, cognitive function, quality of life